Medroxyprogesterone acetate
Pro Research Analysisby 
Searched over 200M research papers for "medroxyprogesterone acetate"
Medroxyprogesterone Acetate: Applications and Implications
Medroxyprogesterone Acetate in Controlled Ovarian Hyperstimulation
Preventing Premature LH Surges
Medroxyprogesterone acetate (MPA) has been shown to be an effective oral alternative for preventing premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF). A study involving 300 patients demonstrated that MPA, when administered with human menopausal gonadotropin (hMG), effectively suppressed LH surges, with an incidence of only 0.7% in the study group. The clinical pregnancy rates, implantation rates, and live-birth rates were comparable to those in the control group, indicating that MPA can be a viable option for ovarian stimulation in combination with embryo cryopreservation.
Behavioral Effects of Medroxyprogesterone Acetate
Impact on Social and Sexual Behavior
Research on female macaques has revealed that MPA can antagonize the effects of estradiol (E2) on sociosexual behavior. While E2 alone increased sexual initiation rates, the addition of MPA significantly reduced these rates and increased aggression. This suggests that MPA may counteract some beneficial behavioral effects of E2, potentially leading to negative affect and increased aggression.
Fertility-Sparing Treatment with Medroxyprogesterone Acetate
Combining MPA with Metformin
MPA, combined with metformin, is being investigated as a fertility-sparing treatment for patients with atypical endometrial hyperplasia (AEH) and endometrial carcinoma (EC). A phase II trial indicated that metformin could inhibit disease relapse after remission. The ongoing FELICIA trial aims to determine the optimal dose of metformin to be used with MPA, with primary endpoints including the 3-year relapse-free survival rate and secondary endpoints such as conception rates and pregnancy outcomes.
Medroxyprogesterone Acetate in Prostate Cancer Treatment
Comparative Efficacy in Advanced Prostatic Cancer
In a randomized phase III trial, MPA was compared with cyproterone acetate and diethylstilbestrol in treating advanced prostatic cancer. The study found that patients treated with MPA had a less favorable course, with shorter survival and time to progression compared to the other treatments. This suggests that while MPA is an option, it may not be the most effective treatment for advanced prostatic cancer.
Safety of Subcutaneous Depot Medroxyprogesterone Acetate
Systematic Review of DMPA-SC
A systematic review evaluated the safety of subcutaneously administered depot medroxyprogesterone acetate (DMPA-SC). The review found that DMPA-SC is generally safe for women with various characteristics or medical conditions, including obesity, endometriosis, and HIV. The safety profiles of DMPA-SC and intramuscular DMPA (DMPA-IM) were found to be similar, with no significant differences in contraceptive efficacy, weight change, or bleeding patterns.
Medroxyprogesterone Acetate and Immune Function
Suppression of Immune Mechanisms
MPA has been shown to suppress both innate and adaptive immune mechanisms, which may contribute to an increased risk of HIV-1 acquisition and transmission. MPA inhibits the production of key cytokines and chemokines, reduces the down-regulation of HIV-1 coreceptors on T cells, and increases HIV-1 replication in activated peripheral blood mononuclear cells. This immunosuppressive effect highlights the need for careful consideration when using MPA in regions with high HIV-1 prevalence.
Drug-Drug Interactions with Medroxyprogesterone Acetate
Interactions with Antiretroviral and Antituberculosis Treatments
MPA, as a cytochrome P450 (CYP3A4) substrate, can interact with antiretroviral and antituberculosis treatments, potentially leading to subtherapeutic concentrations and contraceptive failure. A pharmacokinetic analysis suggested that coadministration with efavirenz or efavirenz plus antituberculosis treatment increases MPA clearance, while lopinavir/ritonavir decreases it. Adjusting the dosing interval to every 8-10 weeks can mitigate the risk of subtherapeutic exposure.
Medroxyprogesterone Acetate in Oocyte Donation
Alternative to GnRH Antagonists
MPA has been found to be a useful alternative to gonadotropin-releasing hormone (GnRH) antagonists in oocyte donation. A randomized controlled trial showed that MPA resulted in similar oocyte retrieval rates, endocrine profiles, and pregnancy outcomes compared to GnRH antagonists. This suggests that MPA can be recommended for ovarian stimulation in oocyte donation, offering a more patient-friendly approach.
Long-Term Safety of Depot Medroxyprogesterone Acetate
Efficacy and Safety Profile
Depot medroxyprogesterone acetate (DMPA) is a highly effective contraceptive with a proven long-term safety profile. It has been associated with minimal cardiovascular risks, a low incidence of breast and gynecologic malignancies, and manageable side effects such as changes in menstrual cycle, body weight, and mood. This makes DMPA a reliable option for long-term contraception.
Treatment of Endometriosis-Associated Pain
Comparison with Leuprolide Acetate
In the treatment of endometriosis-associated pain, DMPA-SC has been shown to be as effective as leuprolide acetate. A phase 3 trial demonstrated that DMPA-SC significantly reduced endometriosis symptoms with less impact on bone mineral density and fewer hypoestrogenic side effects, although it was associated with more irregular bleeding.
Conclusion
Medroxyprogesterone acetate (MPA) is a versatile medication with applications ranging from contraception and fertility treatments to managing endometriosis and advanced prostatic cancer. While it offers several benefits, including effective LH surge prevention and fertility-sparing options, its use requires careful consideration of potential behavioral effects, immune suppression, and drug interactions. Overall, MPA remains a valuable tool in reproductive health, with ongoing research continuing to refine its applications and safety profiles.
Sources and full results
Most relevant research papers on this topic